Westpac Banking Corp’s Haemonetics HAE Stock Holding History

Westpac Banking Corp’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,852	Closed	-$273K	–	516
2026 Q1	$273K	Buy	4,852 +1,271	+35%	+$82.8K	0.02%	324
2025 Q4	$287K	Buy	+3,581	New	+$241K	0.02%	317

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Westpac Banking Corp's HAE Position: Q2 2026 in Review

Westpac Banking Corp sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 4,852 shares — an estimated $273K sold.

Westpac Banking Corp first reported a position in HAE in Q4 2025 and held it in 2 quarters. The position peaked at $287K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Westpac Banking Corp reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
Westpac Banking Corp sold 4,852 Haemonetics shares in Q2 2026, an estimated $273K.
Westpac Banking Corp first reported a position in Haemonetics in Q4 2025 and held it in 2 quarters.
Westpac Banking Corp's Haemonetics position peaked at $287K in Q4 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Westpac Banking Corp's 13F filing for Q2 2026, filed 12 Aug 2026.